Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.
New analysis of the LATTE trial shows the two drugs cabotegravir and rilpivirine may also work as a daily oral formulation, which could be a bridge therapy for people who miss an injectable appointment.
Best Practices for Most Vulnerable Populations: Transgender People, Adolescents, and the Recently Incarcerated
"As we think about the care cascade, we can't even test people [for HIV] to diagnose them if we can't get them in the door to a health care setting," one clinician said.
The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.
Gilead Sciences is working with the federal government to roll out its pre-exposure prophylaxis (PrEP) donation program. Here, we detail what we know so far about how this will be implemented.
Black Women in Atlanta Need More PrEP Access. Researchers and Advocates Are Working to Make This a Reality.
While most pre-exposure prophylaxis (PrEP) campaigns focus on gay and bisexual men, Fulton County Board of Health officials and advocates look for solutions to get PrEP to black women.
If everyone living with HIV gets into care, do we have enough providers to support them? HIV doctors are proposing policy changes to address the workforce shortage.
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.
Grindr Users Take PrEP More and Have Lower HIV Rates, but Have Higher Rate of STIs Than Men Not on the App
Gay and bisexual men who used Grindr were having more sex acts associated with increased risk, but were more likely to use PrEP or be open to it, which translated to lower HIV incidence.
At IDWeek in Washington, D.C., leading infectious disease doctors and researchers met with U.S. Congress leadership to discuss HIV prevention, treatment, and care policy.